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Abstract
Background Hypertension is a leading cause of cardio-
vascular (CV) disease in the general population. Although
hypertension is very common in maintenance hemodialysis
(HD) patients, adequate blood pressure (BP) values and
measurement timing have not been deﬁned.
Methods A total of 49 hypertensive HD patients were
recruited. Average age was 63 ± 11 years, and duration of
dialysis therapy was 6.2 ± 4.2 years. Dialysis unit BPs and
various types of home BPs were separately measured, and
which BPs were the most critical markers in evaluating the
effect of hypertension on left ventricular hypertrophy and
CV events was investigated.
Results Predialysis systolic BPs were not correlated with
any home BPs. Left ventricular mass index (LVMI) had a
signiﬁcant positive correlation with home BPs, especially
morning systolic BPs on HD days (P\0.01) and non-HD
days (P\0.05), on univariate and multivariate analysis. In
contrast, predialysis BPs did not correlate with LVMI.
During the follow-up period (47 ± 18 months), it was
demonstrated that diabetes and home BPs, especially sys-
tolic BPs on the morning of HD days, were signiﬁcant
predictors of CV events on multivariate Cox regression
analysis. A 10 mmHg increase in BP had a signiﬁcantly
elevated relative risk for CV events.
Conclusions Home BP, especially systolic BPs in the
morning on HD days, can provide pivotal information for
management of HD patients.
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Introduction
Hypertension is very common in patients undergoing reg-
ular hemodialysis (HD) treatment. Using various deﬁni-
tions of hypertension, the prevalence of hypertension in
HD patients is estimated to be 60–90% [1–6]; for example,
in a study of 2,535 clinically stable adult HD patients, 86%
were found to be hypertensive [6]. In that study, hyper-
tension was controlled adequately in only 30% of hyper-
tensive patients. In the remaining patients, hypertension
was either untreated (12%) or was poorly controlled (58%).
Cardiovascular (CV) disease is the leading cause of death
in patients receiving maintenance HD. Hypertension of HD
patients is a risk factor for development and progression of
left ventricular hypertrophy (LVH), CV, and total mortality
[7]. Although Kidney Disease Outcomes Quality Initiative
(K/DOQI) guidelines suggest that pre-HD and post-HD
blood pressure (BP) should be \140/90 and \130/
80 mmHg, respectively [8], the optimum BP goals for HD
patients have not yet been deﬁned. A meta-analysis showed
that dialysis unit BP (pre- and post-HD) have poor agree-
ment with interdialytic ambulatory BP [9]. BP obtained
outside the dialysis unit, whether by interdialytic ambula-
tory BP measurement or self-measurement of BP at home,
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DOI 10.1007/s10157-011-0575-1is useful in diagnosing LVH [10]. More recently, home BP
and ambulatory BP have been found to provide superior
prognostic value for all-cause mortality compared with
dialysis unit BP among HD patients [11].
In this study, dialysis unit BP and various types of home
BPs were separately measured, and which BPs were the
most critical markers in evaluating the effect of hyperten-
sion on LVH and CV events in hypertensive HD patients
was investigated.
Subjects and methods
Protocol
The protocol was in conformity with the ethical guidelines
of our institutions, and informed consent was obtained
from each participant.
Subjects
Forty-nine patients with end-stage renal disease (ESRD)
(28 men and 21 women) who had been on regular dialysis
treatment for at least 6 months at The Jikei University
Kashiwa Hospital and Shin-Kashiwa Clinic were eligible
for the study. All patients had been prescribed antihyper-
tensive agents with diagnosis of hypertension. Patients with
signiﬁcant cardiac valvular disease, congestive heart failure
with ventricular ejection fraction below 40%, or malignant
disorders were excluded. No patients had experienced
previous CV diseases. All patients underwent standard
3-times-a-week bicarbonate dialysis. All patients were on
antihypertensive treatment [49 on calcium channel block-
ers (CCBs), 28 on angiotensin II receptor blockers (ARBs),
15 on alpha blockers, and 3 on beta blockers] with various
combinations.
After the initial assessment, patients were followed for
56 months. During the follow-up period, CV events (fatal
and nonfatal coronary heart disease diagnosed by coronary
angiography, fatal arrhythmia, peripheral artery disease,
transient ischemic attacks, stroke, and aortic dissection)
and death were evaluated. To assess CV events and death
accurately, two physicians checked the patients’ medical
records. Coronary heart diseases were suspected by chest
symptoms and electrocardiographic ﬁndings, and diag-
nosed by coronary angiography. Arrhythmias were diag-
nosed based on a standard 12-lead electrocardiogram.
Cerebral stroke and transient ischemic attacks were diag-
nosed by neurological signs and symptoms together with
computed tomography (CT) or magnetic resonance imag-
ing. Peripheral artery disease and aortic dissection were
diagnosed by clinical symptoms and enhanced CT ﬁndings.
Measurement of left ventricular mass
Echocardiographic measurements were performed with a
digital cardiac ultrasound machine on a midweek nondi-
alysis day. M-mode echocardiogram measurements of
interventricular septal thickness (IVSTd), posterior wall
thickness (PWTd), and left ventricular internal diameter
(LVIDd) were performed at end diastole according to
established standards of the American Society of Echo-
cardiography (ASE). Left ventricular mass (LVM) was
calculated using the formula by Devereux et al. [12]
according to the ASE guidelines:
LV mass ðg) ¼ 0:8ð1:04ð½IVSTd þ PWTd þ LVIDd]3
 ½ LVIDd 
3ÞÞ þ 0:06:
Echocardiography was performed by the same technician,
and all measurements were performed in duplicate by the
same cardiologist, who was unaware of the subject’s BP.
Left ventricular mass index (LVMI) was derived by
dividing LVM in grams by the body surface area.
Predialysis BPs
AsinglepredialysisBPmeasurementwastakenbyadialysis
unit staff member with patients in sitting position, within
30 min prior to the dialysis session using an automated
sphygmometer on the nonﬁstula arm. Predialysis BP was
calculatedastheaveragevalueof9recordingsover3 weeks.
Home BPs
Home BP monitoring was performed 2 times daily for
3 weeks. Patients were asked to record their BP on waking
up and before going to bed in sitting position using a
validated self-inﬂating automatic oscillometric device.
Four home BP values (morning BP and night BP on HD
and non-HD days) were separately evaluated.
Statistical analysis
Subject characteristics are presented as mean ± standard
deviation (SD) or median and interquartile range for con-
tinuous variables as appropriate, and number (percent) for
categorical data. All BP measurements are reported as
mean ± SD. Univariate and multivariate analyses were
performed to evaluate the correlations between LVMI and
several factors. The prognostic value for CV event of
predialytic and home BPs was analyzed by multivariate Cox
regression analysis. As potential confounders, a set of well-
established risk factors in dialysis patients was consid-
ered: age, gender, HD duration, diabetes, antihypertensive
(especially ARB) therapy, and clinical data. Hazard ratios
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123(HR) and their 95% conﬁdence intervals (CI) were calcu-
lated with the use of the estimated regression coefﬁcients
and their standard errors in the Cox regression analysis. All
analyses were conducted using SPSS software version 17.0
(SPSS, Chicago, IL, USA) for Windows. The P values
reported are two sided and taken to be signiﬁcant at\0.05.
Results
Clinical characteristics of the patients are presented
in Table 1. Average age was 63 ± 11 years (range
37–84 years), and duration of dialysis therapy was
6.2 ± 4.2 years (range 1–16 years). Interdialytic body
weight (BW) gain was 3.9% per dry weight, and post-HD
cardiothoracic ratio (CTR) was 48.4%. Intradialytic hypo-
tension episodes were not found in any patient during the
week in which the measurements were performed. All of
the patients had been treated with antihypertensive drugs:
49 (100%) were on CCBs, 28 (57.1%) were on ARBs, 15
(30.6%) were on alpha blockers, and 3 (6.1%) were on beta
blockers, with various combinations.
Table 2 presents the values of predialysis BPs and each
home BP. Predialysis mean systolic BP was 152.8 ±
19.0 mmHg. Each mean systolic home BP was as follows:
mornings on HD days 155.8 ± 17.8 mmHg, nights on HD
days 152.3 ± 19.6 mmHg, mornings on non-HD days
150.9 ± 18.4 mmHg, and nights on non-HD days
156.1 ± 17.1 mmHg. The value of BP in the morning on
HD days was signiﬁcantly higher than BP in the morning
on non-HD days (P\0.05). There were no differences
between diastolic BPs. Predialysis systolic BPs were not
correlated with any home BPs. The difference between HD
morning and non-HD morning BPs was weakly correlated
with % interdialytic BW gain (P = 0.05, data not shown).
Predialysis and home BPs and LVMI
As shown in Fig. 1, home BPs, especially morning systolic
BPs on HD and non-HD days, had a signiﬁcant positive
correlation with LVMI (r = 0.50, P\0.01 and r = 0.41,
P\0.01, respectively). On the other hand, predialysis BP
did not correlate with LVMI (r = 0.27, NS). Multivariate
analysis including various factors (HD vintage, age, gen-
der, diabetes, ARB, and BPs) demonstrated that only
morning systolic BPs on HD and non-HD days had sig-
niﬁcant correlation with LVMI (Table 3).
Predialysis and home BPs and cardiovascular events
During the follow-up period (47 ± 18 months), 11 (22%)
patients had CV events (4 with angina, 4 with stroke, 2
with idiopathic ventricular tachycardia, and 1 with aortic
dissection). Among these patients, 3 patients died with
stroke. Table 4 presents the relative risks (RR) of CV
Table 1 Clinical characteristics and antihypertensive agents of study
subjects
Clinical characteristic n = 49
Male (%) 28 (57.1)
Age (years) 63 ± 11 (37–84)
HD duration (years) 6.2 ± 4.2 (1–16)
Diabetes mellitus (%) 16 (32.6)
Post-HD CTR (%) 48.4 ± 4.2 (41.3–59.8)
Interdialytic body weight gain
/dry weight (%) 3.99 ± 0.99
BUN (mg/dl) 65.9 ± 14.7
Cr (mg/dl) 11.6 ± 2.5
Alb (g/dl) 3.9 ± 0.3
Ca (mg/dl) 8.9 ± 0.8
P (mg/dl) 4.4 ± 1.1
Hb (g/dl) 10.0 ± 0.9
Antihypertensive agents
CCB (%) 49 (100)
ARB (%) 28 (57.1)
a Blocker (%) 15 (30.6)
b Blocker (%) 3 (6.1)
CTR cardiothoracic ratio, BUN blood urea nitrogen, Cr creatinine, Alb
albumin, Ca calcium, P phosphate, Hb hemoglobin, CCB calcium
channel blockers, ARB angiotensin receptor blockers
Table 2 Predialysis and home BP measurements
BPs mmHg
Clinic
Predialysis
Systolic 152.8 ± 19.0
Diastolic 80.2 ± 13.4
Home
Mornings on HD days
Systolic 155.8 ± 17.8
a
Diastolic 80.9 ± 14.5
Nights on HD days
Systolic 152.3 ± 19.6
Diastolic 81.7 ± 14.4
Mornings on non-HD days
Systolic 150.9 ± 18.4
a
Diastolic 80.6 ± 12.4
Nights on non-HD days
Systolic 156.1 ± 17.1
Diastolic 81.1 ± 12.9
a BP in the morning on HD days versus BP in the morning on non-
HD days, P\0.05
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123events in the study population. As assessed by multivariate
Cox analysis, the signiﬁcant predictors of CV events were
diabetes and home BPs, especially systolic BPs on the
morning of HD days. A 10 mmHg increase in BP had a
signiﬁcantly elevated RR for CV events (RR 2.00, 95% CI
1.07–3.74, P = 0.03).
Discussion
The results demonstrated that the median systolic values of
predialysis and home BPs were around 150 mmHg, rang-
ing from 151 to 156 mmHg, while the median diastolic
values were around 80 mmHg. Predialysis systolic BPs
were higher than the K/DOQI guideline (\140/90 mmHg)
[8]. All patients in the present study had been diagnosed
with hypertension before, and treated with at least one or
more antihypertensive agents. Despite aggressive treat-
ment, BP control was considered to be inadequate by the
K/DOQI guideline. The 12th annual report of the UK Renal
Registry (UKRR) indicated that 43.1% of HD patients
achieve predialytic BP of \140/90 mmHg [13]. Strict
control of BPs is often difﬁcult, considering the prevention
of hypotension during HD. Davenport et al. [14] reported
that intradialytic hypotension was signiﬁcantly greater in
centers that achieved better postdialysis BP targeting.
The present data showed that predialysis systolic BPs
were not correlated with any home BPs. Agarwal et al. [15]
reported that BPs obtained before and after dialysis, even if
obtained using standardized methods, agree poorly with
interdialytic ambulatory BP. In contrast, home BP served
as a useful predictor of hypertension diagnosed by ambu-
latory BP monitoring. The difference between HD and
non-HD morning BPs was weakly correlated with %
interdialytic BW gain. This is reasonable because BPs in
HD patients, in part, usually depend on an increase in ﬂuid
volume between dialysis.
The present study demonstrated that LVMI had a sig-
niﬁcant positive correlation on univariate analysis with
home BP, especially morning systolic BPs on HD and non-
HD days. In contrast, predialysis BP did not correlate with
LVMI. Multivariate analysis including several factors
which could affect LVMI demonstrated that only morning
systolic BPs on HD and non-HD days were regarded as
independent explanatory factors. LVMI has been reported
as a critical indicator to predict mortality and CV outcomes
in patients undergoing dialysis [16–19]. LVH regression in
patients with ESRD has been shown to have a favorable
and independent effect on patients’ all-cause and CV sur-
vival [20]. Agarwal et al. [10] reported that dialysis unit
BPs in 140 HD patients were weak correlates of LVH. On
the other hand, systolic BPs outside the dialysis unit
(1-week averaged home BP readings) were a stronger
correlate of LVH. Diastolic BPs, regardless of the mea-
surement technique, were of little use in detecting LVH. A
more recent study reported that weekly averaged BP
(WAB) was a useful marker that reﬂects BP variability
LVMI
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Fig. 1 Correlation with left ventricular mass index (LVMI) and
various types of blood pressures (BPs). LVMI demonstrated signif-
icant correlation with morning BPs on hemodialysis (HD) (R = 0.50,
P\0.01) and non-HD (R = 0.41, P\0.01) days. In contrast, LVMI
did not have a correlation with predialysis BPs (R = 0.27, NS)
Table 3 Correlation with LVMI and various factors assessed by
multivariate analysis
Model 1 Model 2
RP RP
HD duration 0.03 0.83 0.03 0.84
Age 0.02 0.87 0.05 0.76
Gender -0.22 0.19 -0.26 0.15
DM -0.15 0.35 -0.05 0.77
ARB 0.12 0.45 0.18 0.30
BPs (mmHg)
Predialysis 0.27 0.12 0.31 0.09
Home
Mornings on HD days 0.57 0.008
Nights on HD days 0.20 0.44 -0.12 0.67
Mornings on non-HD days 0.55 0.03
Nights on non-HD days -0.32 0.27 -0.15 0.60
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123during 1 weekand correlates with target organ damage such
as LVMI and brachial-ankle pulse wave velocity (PWV)
[21]. Furthermore, systolic and diastolic WAB are almost
completely consistent with BPs taken immediately after
waking up on the next day after the middle dialysis session.
The present data agree with these previous studies. It should
be emphasized that home BPs, especially morning systolic
BPs on HD days, play a pivotal role predicting LVMI. This
phenomenonisconsideredtobereasonablebecausemorning
BPs on HD days can partly represent maximum volume
overload to vasculature, thus affecting LVMI.
The present results also demonstrated that home BPs,
especially systolic BPs on the morning of HD days, were
the signiﬁcant predictors of CV events during follow-up
period. A 10 mmHg increase in BP had a signiﬁcantly
elevated RR for CV events (RR 2.00). Several studies
using ambulatory or home BP monitoring in HD patients
support the concepts that ambulatory BP and mortality are
strongly related. Amar et al. [22] reported that nocturnal
BP and 24-h pulse pressure were independent predictors of
CV mortality in 57 treated hypertensive HD patients
(34 ± 20 months). Tripepi et al. [23] analyzed the prog-
nostic power of 24-h ambulatory BP monitoring for all-
cause and CV mortality in 168 nondiabetic, event-free HD
patients (38 ± 22 months). The ratio of the average sys-
tolic BP during the night and day (night/day systolic ratio)
used to indicate the nocturnal fall in BP was associated
with all-cause and CV mortality. Moriya et al. [24]
reported that WAB could be a good prognostic marker of
the incidence of both CV events and all-cause mortality in
96 HD patients (35 months). Recently, Agarwal [11]
evaluated the presence, strength, and shape of the rela-
tionship between BP measured using different modalities
(home, ambulatory, and dialysis unit) and all-cause
mortality among 326 HD patients (32 ± 20 months).
Out-of-dialysis unit BP was reported as prognostically
more informative than that recorded just before and after
dialysis.
The role of hypertension as a risk factor for increased
CV events in the general population is indisputable.
However, a lot of studies have shown an association
between low BP and increased mortality, or have shown a
U-shaped relationship, with both low and high BP associ-
ated with increased RR of death [25–27]. These paradox-
ical observations have been referred to as ‘‘reverse
epidemiology’’ [28]. As the etiology of this inverse asso-
ciation between conventional risk factors and clinical
outcome is not clear, presence of malnutrition and
inﬂammation may explain the existence of reverse epide-
miology in dialysis patients. In the present study, patients
who were recently hospitalized or sick were excluded. All
of the patients in the present study had hypertension, nor
pre- and postdialysis hypotension. Thus, this study differed
in its recruitment criteria compared with previous studies
which have analyzed all patients in the dialysis unit
regardless of their level of illness.
In the present statistical evaluation, age did not con-
tribute to the onset of CV events. Several reasons are
considered to explain this phenomenon. First, the obser-
vation period was likely short to evaluate CV events.
Second, patients in the present study had not experienced
previous CV diseases. Third, few fatal events occurred,
probably due to their healthy condition for dialysis patients.
Allofthepatientsinthepresentstudyhadbeenprescribed
one or more antihypertensive agents: 49 (100%) were on
CCBs, 28(57.1%)were on ARBs, 15 (30.6%)were on alpha
blockers, and 3 (6.1%) were on beta blockers. Recent data
from the Dialysis Outcomes and Practice Patterns Study II
(DOPPS II) showed that prescription of antihypertensive
agentclassesvariedsigniﬁcantlybycountry,rangingforbeta
blockers from 9.7% in Japan to 52.7% in Sweden, for ARBs
from 5.5% in Italy to 21.3% in Japan, and for CCBs from
19.5% in Belgium to 51.4% in Japan [29]. Therefore, the
highproportionofprescribedCCBsandARBsinthepresent
study in Japan is not so surprising.
The ability to generalize the results of this study may be
limited because of the number of patients and clinical
characteristics. The number of patients was too small to
conclude prognosis of a large variety and complexity of
HD patients. Patients included in this study were all
hypertensive and were treated with one or more antihy-
pertensive agents. Furthermore, almost all patients were in
good health. Recently, diurnal BP variation has been con-
sidered important [30]. In the present study, ambulatory
BPs were not measured. Ambulatory BP monitoring pro-
vides not only static but also dynamic information about
BP that should be considered to ensure effective manage-
ment of hypertension and CV diseases.
Table 4 Relative risk of cardiovascular events assessed by multi-
variate Cox proportional hazards models
Relative
risk
95% conﬁdence
limits
P
HD duration 1.19 0.93–1.52 0.17
Age 1.06 0.97–1.15 0.21
Gender 1.93 0.20–18.9 0.57
DM 8.76 1.30–58.9 0.03
ARB 1.16 0.18–7.50 0.88
Cr 1.20 0.77–1.87 0.41
Alb 1.69 0.09–33.7 0.73
Ca 1.14 0.34–3.79 0.83
P 0.44 0.17–1.18 0.10
Hb 1.10 0.45–2.66 0.84
BPs (10 mmHg)
Mornings on HD days 2.00 1.07–3.74 0.03
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123In conclusion, the results of the present study are: (1)
predialysis systolic BPs were not correlated with any home
BPs; (2) LVMI had a signiﬁcant positive correlation with
home BPs, especially morning systolic BPs on HD and
non-HD days; and (3) home BPs, especially systolic BPs in
the morning on HD days, were signiﬁcant predictors of CV
events during the follow-up period. Prospective interven-
tion studies with large numbers of patients will be needed
to clarify the cause–effect relationship between various
BPs and CV events.
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